CME

CME


Latest Episodes

Fixed-Duration vs Continuous-Dosing Approaches in CLL: Impact on QoL and Toxicity Risk
August 16, 2024

Host: William Wierda, MD, PhD Determining the optimal treatment regimen for patients with chronic lymphocytic leukemia (CLL) has been a clinical challenge, especially since most patients are older than 70 years, present with significant coexisti

Combination Therapy in CLL: Identifying the Right Patient for the Right Treatment Approach
August 16, 2024

Host: Thomas Kipps, MD, PhD Host: William Wierda, MD, PhD Determining the optimal treatment regimen for patients with chronic lymphocytic leukemia (CLL) has been a clinical challenge, especially since most patients are older than 70 years, p

Combination Therapy for CLL: What Evidence Do We Have?
August 16, 2024

Host: William Wierda, MD, PhD Determining the optimal treatment regimen for patients with chronic lymphocytic leukemia (CLL) has been a clinical challenge, especially since most patients are older than 70 years, present with significant coexisti

MRD Testing to Guide Treatment Considerations in CLL
August 16, 2024

Host: Talha Munir, PhD Determining the optimal treatment regimen for patients with chronic lymphocytic leukemia (CLL) has been a clinical challenge, especially since most patients are older than 70 years, present with significant coexisting como

Myeloma Matters: Bispecific Antibody Horizons: Dosing Strategies and Meeting Updates in Myeloma Care
August 15, 2024

Host: Saad Z. Usmani, MD, MBA, FACP Guest: Joshua Richter, MD Guest: Ashley Steinberger, APP Release date: 8/15/2024Expiration date: 8/15/2025Estimated time to complete: 1.0 hour This activity is not accredited for CME/CE credit. This ep

HER2-Targeted ADCs in Advanced NSCLC: A Case-Based Approach to Targeted Treatment for Metastatic Disease
August 13, 2024

Host: Justin Gainor, MD Guest: Jacob Sands, MD The treatment landscape of non-small cell lung cancer (NSCLC) has dramatically changed over the past 20 years. In recent years, the discovery of targetable molecular alterations and the developm

Case in Point: The Use of GnRH Antagonists Pre- and/or Post-Surgery and the Potential Consequences of Repeat Surgery
August 09, 2024

Host: Lee P. Shulman, MD, FACMG, FACOG Guest: Ayman Al-Hendy, MD, PhD, FRCSC, FACOG, CCRP Guest: James A. Simon, MD, CCD, NCMP, IF, FACOG While both medical therapy and surgery often play a role in a womans journey with endometriosis, i

Patient-Centric Tools to Support Shared Decision-Making: Diagnosing and Assessing Endometriosis
August 09, 2024

Host: Lee P. Shulman, MD, FACMG, FACOG Guest: Linda Bradley, MD Guest: Melissa Simon, MD The use of validated patient questionnaires, notably the SF-36 and EHP-30 scales, can greatly hasten the suspicion for an endometriosis diagnosis. C

Pain Points: Weighing the Benefits and Drawbacks of the GnRH Antagonists Throughout the Endometriosis Treatment Journey
August 09, 2024

Host: Lee P. Shulman, MD, FACMG, FACOG Guest: Ayman Al-Hendy, MD, PhD, FRCSC, FACOG, CCRP Guest: Sawsan As-Sanie, MD GnRH antagonists have emerged as a viable first-line (or subsequent-line) medical therapy for the management of endometr

Creating a Practice Environment That Enhances Healthcare Equality for All Patients
August 09, 2024

Host: Lee P. Shulman, MD, FACMG, FACOG Guest: Linda Bradley, MD Guest: Melissa Simon, MD Both provider- and patient-related healthcare disparities exist in the diagnosis and management of endometriosis. Many disparities derive from incor